Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;56(10):898-903.
doi: 10.1007/s00117-016-0168-9.

[Neurosarcoidosis]

[Article in German]
Affiliations
Review

[Neurosarcoidosis]

[Article in German]
W Reith et al. Radiologe. 2016 Oct.

Abstract

Clinical/methodical issue: Neurosarcoidosis is a relatively rare complication of sarcoidosis that occurs in approximately 5-15 % of patients. The clinical picture is variable. Clinically, neurosarcoidosis is mostly manifested as lesions of the cranial nerves (50-70 %) and several cranial nerves are typically affected. This is the result of aseptic granulomatous basal meningitis. Intraparenchymal granulomas also occur, frequently affecting basal near-midline structures, such as the hypothalamus and pituitary glands and can lead to encephalopathy.

Standard radiological methods: Diagnostics are essentially performed using magnetic resonance imaging (MRI) as it can demonstrate the thickened meninges, which have a high affinity for contrast media but the results are not specific. Particularly in the absence of systemic sarcoidosis, diagnosis can be difficult. Laboratory tests are not very sensitive and specific, which makes neurosarcoidosis a diagnostic challenge.

Achievements: Due to the substantial morbidity of the disease, early and consistent treatment should be initiated. This is usually carried out with corticosteroids supported by immunosuppressant drugs, such as azathioprine and methotrexate.

Keywords: Corticosteroids; Magnetic resonance imaging; Neurotuberculosis; Sarcoidosis; Therapy.

PubMed Disclaimer

References

    1. Eur Respir J. 2003 Mar;21(3):407-13 - PubMed
    1. Radiologe. 2014 Aug;54(8):764-71 - PubMed
    1. Curr Opin Neurol. 2004 Jun;17(3):311-6 - PubMed
    1. Pharmacotherapy. 2005 Sep;25(9):1181-92 - PubMed
    1. N Engl J Med. 1997 Apr 24;336(17):1224-34 - PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources